AMGN
Amgen Inc.
Amgen (AMGN) Q2 2026 earnings
Published Aug 4, 2026
AI summary
- Revenue $10.1B, up 10% from $9.18B a year ago.
- Adjusted EPS $6.29, up from $6.02 a year ago.
- Total revenue for the second quarter of 2026 rose 10% year-over-year to $10.1 billion.
- GAAP diluted EPS increased 65% to $4.37, while non-GAAP EPS grew 4% to $6.29.
- Product sales grew 9% overall, supported by strong performance from key growth drivers.
Results vs analyst consensus
Revenue
Reported
$10.1B
Consensus not captured before release
+10% YoY
Adjusted EPS
Reported · Non-GAAP EPS
$6.29
Consensus not captured before release
GAAP EPS: $4.37
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
$38.2B–$39.4B
full year 2026 revenue guidance
Next-quarter consensus not captured before release.
What to watch
- Sales of Prolia and XGEVA declined significantly due to biosimilar competition.
- The FDA has requested a voluntary withdrawal of TAVNEOS from the U.S. market.
- Subcutaneous blinatumomab studies are currently paused following an FDA partial clinical hold.
Read original report
Source: Amgen Inc. press release · SEC Form 8-K exhibit 99.1